Arrowhead Pharmaceuticals Gears Up for November 2024 Key Events in Gene Therapy

Arrowhead Pharmaceuticals Prepares for Key Events in November 2024

Arrowhead Pharmaceuticals, Inc. is set to make significant contributions to the field of gene therapy and RNA interference during a series of high-profile events in November 2024. Central to the company’s agenda is the presentation of critical findings related to Plozasiran (ARO-APOC3), a GalNAc-siRNA conjugate designed to address severe hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD) associated with mixed hyperlipidemia. Presenter Jack Shi will lead poster sessions at the 15th Annual American Conference on Pharmacometrics (ACoP 2024) from November 10-13, showcasing the population kinetic-pharmacodynamic modeling of Plozasiran. This innovative approach emphasizes Arrowhead’s commitment to developing targeted therapies that tackle complex metabolic disorders.

Moreover, Arrowhead’s engagement at the UBS Global Healthcare Conference on November 12, 2024, is highlighted by a fireside chat, offering insights into the company's strategic direction and pipeline advancements. Following this, Jing Chen will discuss the revolutionary TRiM™ platform for oligonucleotide delivery at the TIDES Europe event, scheduled for November 14. This platform represents Arrowhead's continued innovation in the field of RNA therapeutics, which is critical for the effective delivery of oligonucleotides to target tissues, thereby enhancing treatment efficacy and safety.

Further solidifying its presence in the cardiovascular and metabolic disease landscape, Arrowhead will present at the American Heart Association (AHA) Scientific Sessions 2024. Key presentations include the PALISADE Phase 3 study, where Gerald Watts will assess the efficacy and safety of Plozasiran for patients at high risk of acute pancreatitis due to familial chylomicronemia syndrome. Additionally, Christie Ballantyne will share long-term data on Plozasiran’s performance. Arrowhead will also focus on Fazirsiran during The Liver Meeting 2024, reinforcing its dedication to addressing Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. These presentations underscore Arrowhead’s robust pipeline and its dedication to delivering innovative treatments that can significantly improve patient outcomes.

In addition to these events, Arrowhead Pharmaceuticals plans to host a webcast and conference call on November 26, 2024, to discuss its financial results for the fiscal year ending September 30, 2024. This call will highlight the company’s fiscal performance and outlook, allowing investors to engage directly with the management team. Arrowhead continues to emphasize the importance of transparency and investor relations as it navigates the complexities of the biopharmaceutical industry.

As Arrowhead Pharmaceuticals gears up for these pivotal events, its focus remains on advancing RNA-based therapies that leverage the body’s natural biological processes. With a commitment to innovation and patient-centered care, the company is well-positioned to influence the future landscape of treatments for intractable diseases.